Replies to post #8218 on Pluristem Therapeutics Inc (PSTI)

[Scott999]

Too thinly may be the operative word there Jasper. In CLI, the patients are followed for 3 years, so we have a while for that. Hip study, they are followed for a year. ARS...needs to start then I'd imagine 6 months to a year. Japan fast track is just a joke. So without a partnership with some cash, I don't see us making it to any finish line without serious dilution.

Hence the concern going to a ton of shows. Maybe they are anticipating something big and then want to promote it. Month and a half to year end. Hoping we get some clarity on something from them, not just the usual rehashing of stuff we already know. I/C results will be extremely important and better be clearly positive. Otherwise that casts serious doubts on CLI as well.

[zzaatt]

My fear is that the company have spread
themselves too thinly too many trials too slow recruitment

We have no choice but to trust
and hope that management is aware of these very issues, and that
they're making the right decisions.
We, on the outside simply lack the information to make a judgement
on that, and my feeling is that the combined braintrust of Pluristem
will be able to make the right assessment.